Pharsight

1. List of Azstarys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928	COMMAVE THERAP	Methylphenidate-oxoacid conjugates, processes of making and using the same	Jul, 2032 (9 years from now)
US10584113	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10858341	COMMAVE THERAP	Compositions comprising methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10954213	COMMAVE THERAP	Compositions comprising methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10759778	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)

Do you want to check out AZSTARYS patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 7, 2026

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL